PDCD1 and non-small cell lung carcinoma: In a subsequent phase I clinical trial, Lacey and Fraietta [94] implanted edited T cells into patients with advanced NSCLC, and Wang et al. [95] injected PD-1 gene-edited mesotheliin-specific CAR T cells (MPTK-CAR T cells) into patients with solid tumours.